Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Operating Leases (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Operating Leases readings, the most recent being $6.0 million for Q4 2023.

  • On a quarterly basis, Operating Leases fell 11.52% to $6.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $6.0 million, a 11.52% decrease, with the full-year FY2023 number at $6.0 million, down 11.52% from a year prior.
  • Operating Leases hit $6.0 million in Q4 2023 for Elicio Therapeutics, down from $6.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $7.4 million in Q2 2023 to a low of $297000.0 in Q1 2023.
  • Median Operating Leases over the past 4 years was $3.8 million (2020), compared with a mean of $4.2 million.
  • The widest YoY moves for Operating Leases: up 147.63% in 2023, down 90.82% in 2023.
  • Elicio Therapeutics' Operating Leases stood at $3.8 million in 2020, then decreased by 9.67% to $3.5 million in 2021, then surged by 95.37% to $6.8 million in 2022, then fell by 11.52% to $6.0 million in 2023.
  • The last three reported values for Operating Leases were $6.0 million (Q4 2023), $6.2 million (Q3 2023), and $7.4 million (Q2 2023) per Business Quant data.